The European Medicines Agency (EMA) has implemented updated regulations regarding the disclosure of information on clinical trials submitted through the EU Clinical Trials Information System (CTIS). These enhancements aim to streamline the accessibility of clinical trial data to various stakeholders, including patients and healthcare professionals, in a more expeditious and effective manner.

A notable modification in the new guidelines is the elimination of the deferral mechanism, which previously permitted sponsors to postpone the publication of specific data and documents for a maximum of seven years following the trial’s conclusion. This measure was initially implemented to safeguard personal data and commercially sensitive information (CCI).

The revised rules strike a harmonious balance between promoting information transparency and safeguarding commercially sensitive data. They prove advantageous for patients, as critical clinical trial information highlighted by patients is now published earlier. Additionally, they introduce simplified processes that benefit clinical trial sponsors tasked with protecting commercially sensitive information and personal data. Moreover, healthcare professionals benefit from a more user-friendly system that facilitates easy access to information regarding clinical trials and facilitates enrollment, thereby fostering a greater understanding of potential treatment options.

These updates were prompted by feedback from stakeholders and insights gained following the system’s launch. A comprehensive eight-week public consultation was conducted from May to June 2023.

The implementation of the updated transparency rules will commence following their technical integration into CTIS, along with its public portal, which is projected to reach completion by the second quarter of 2024. The precise date of the implementation process’s finalization and the enforcement of the new rules will be communicated to system users well in advance of their application.

Read the report here.

References

  1. Ema. (2023, October 6). Revised transparency rules for the EU Clinical Trials Information System (CTIS) – European Medicines Agency. European Medicines Agency. https://www.ema.europa.eu/en/news/revised-transparency-rules-eu-clinical-trials-information-system-ctis

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred